Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1435-1440

  Murata, Masashi ^a  

^a Drug Research Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOMYCIN C; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL CELL WALL; CANCER IMMUNOTHERAPY; CELL COUNT; CELL STRAIN HEK293; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSKELETON; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RECEPTOR BINDING; EMBRYO; ENZYME ACTIVATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INHIBITION KINETICS; INNATE IMMUNITY; KNOCKOUT MOUSE; LEWIS CARCINOMA; LYMPHATIC DRAINAGE; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PERITONEAL EXUDATE CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; RECEPTOR UPREGULATION; REPORTER GENE; SPLEEN CELL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE, TUMOR; CELL WALL SKELETON; DENDRITIC CELLS; FEMALE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS; TH1 CELLS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 44449120076     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00832.x     Document Type: Article

References (38)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-15.
2. Blattman JN, Greenberg PD. Cancer immunotherapy: A treatment for the masses. Science 2004; 305: 200-5.
3. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
4. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
5. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001; 413: 732-8.
6. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-7.
7. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
8. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
9. Garay RP, Viens P, Bauer J et al. Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563: 1-17.
10. Schneider C, Schmidt T, Ziske C et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004; 53: 355-61.
11. Shingu K, Kruschinski C, Luhrmann A et al. Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung. Am J Respir Cell Mol Biol 2003; 28: 316-21.
12. Azuma I, Ribi EE, Meyer TJ, Zbar B. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst 1974; 52: 95-101.
13. Koike Y, Yoo YC, Mitobe M et al. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. Vaccine 1998; 16: 1982-9.
14. Granatek CH, Ezaki K, Hersh EM, Keating MJ, Rasmussen S. Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy. Cancer 1981; 47: 272-9.
15. Azuma I, Kanetsuna F, Taniyama T, Yamamura Y, Hori M. Adjuvant activity of mycobacterial fractions. I. Purification and in.vivo adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroides 131 and Corynebacterium diphtheriae PW8. Biken J 1975; 18: 1-13.
16. Meyer TJ, Ribi EE, Azuma I, Zbar B. Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma. J Natl Cancer Inst 1974; 52: 103-11.
17. Taniyama T, Azuma I, Aladin AA, Yamamura Y. Effect of cell-wall skeleton of Mycobacterium bovis BCG on cell-mediated cytotoxicity in tumor-bearing mice. Gann 1975; 66: 705-9.
18. Tsuji S, Matsumoto M, Takeuchi O et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: Involvement of toll-like receptors. Infect Immun 2000; 68: 6883-90.
19. Uehori J, Matsumoto M, Tsuji S et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun 2003; 71: 4238-49.
20. Uenishi Y, Okada T, Okabe S, Sunagawa M. Study on the cell wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105): Establishment of preparation and analytical methods. Chem Pharm Bull (Tokyo) 2007; 55: 843-52.
21. Takeuchi O, Hoshino K, Kawai T et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11: 443-51.
22. Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-52.
23. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11: 115-22.
24. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27.
25. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869-77.
26. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54: 777-85.
27. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165: 618-22.
28. Manthey CL, Perera PY, Henricson BE, Hamilton TA, Qureshi N, Vogel SN. Endotoxin-induced early gene expression in C3H/HeJ (Lpsd) macrophages. J Immunol 1994; 153: 2653-63.
29. Manthey CL, Vogel SN. Elimination of trace endotoxin protein from rough chemotype LPS. J Endotoxin Res 1994; 1: 84-91.
30. Ballas ZK, Krieg AM, Warren T et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 2001; 167: 4878-86.
31. Bedwell J, Kairo SK, Behr MA, Bygraves JA. Identification of substrains of BCG vaccine using multiplex PCR. Vaccine 2001; 19: 2146-51.
32. Ikeda N, Honda I, Yano I, Koyama A, Toida I. Bacillus Calmette-Guerin Tokyo172 substrain for superficial bladder cancer: Characterization and antitumor effect. J Urol 2005; 173: 1507-12.
33. Matsuo T, Matsuo H, Ohara N et al. Cloning and sequencing of an MPB70 homologue corresponding to MPB83 from Mycobacterium bovis BCG. Scand J Immunol 1996; 43: 483-9.
34. Uehori J, Fukase K, Akazawa T et al. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: Monoacylated MDP confers TLR2/ TLR4 activation. J Immunol 2005; 174: 7096-103.
35. Fujimoto Y, Inamura S, Kawasaki A et al. Chemical synthesis of peptidoglycan fragments for elucidation of the immunostimulating mechanism. J Endotoxin Res 2007; 13: 189-96.
36. Ishiwata A, Akao H, Ito Y, Sunagawa M, Kusunose N, Kashiwazaki Y. Synthesis and TNF-α-inducing activities of mycoloyl-arabinan motif of mycobacterial cell wall components. Bioorg Med Chem 2006; 14: 3049-61.
37. Akazawa T, Masuda H, Saeki Y et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 2004; 64: 757-64.
38. Su SB, Silver PB, Grajewski RS et al. Essential role of the MyD88 pathway, but nonessential roles of TLR 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J Immunol 2005; 175: 6303-10.